IBRX-042 / ImmunityBio - LARVOL DELTA

QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Head and Neck tumors (AHNS 2026) - P1 | "The QUILT-3.100 trial successfully enrolled participants to determine the MTD (5e11 VP/dose) for IBRX-042 in participants with HPV-associated solid tumors, including head and neck. The safety profile for this HPV-directed cancer vaccine was well tolerated with no DLTs and future clinical studies in combination with other immune-activating therapies are planned."

Clinical • P1 data • Atrial Fibrillation • Head and Neck Cancer • Hypertension • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Respiratory Diseases • Solid Tumor

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P2 trial • Brain Cancer • Glioblastoma • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

QUILT-3.100: IBRX-042 In Participants With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: ImmunityBio, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2025 ➔ Sep 2027

Enrollment closed • Trial primary completion date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: ImmunityBio, Inc. | Not yet recruiting ➔ Recruiting | N=18 ➔ 12 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Enrollment change • Enrollment open • Trial primary completion date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Mar 2024 ➔ Jun 2024

Trial initiation date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Aug 2023 ➔ Mar 2024

Trial initiation date • Oncology

IBRX-042 In Subjects With HPV-Associated Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P1 trial • Oncology